• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Can a Blood Test Diagnose Depression?

Can a Blood Test Diagnose Depression?

May 1, 2012
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Subject:
Depression

Short Description:
Can a Blood Test Diagnose Depression?

Background:

Psychiatrists have long wondered whether someday we might have an objective way to diagnose depression, in much the same way an internist orders a blood test or X-ray. A recent article suggests that just such a test might be on the horizon. Is it the real deal?

Investigators obtained blood samples from depressed and non-depressed patients. They measured levels of nine “biomarker” proteins and performed a calculation to get an “MDDScore.” The details of the calculation are undisclosed, proprietary information, but the end result is straightforward: a number on a scale of 0 to 100, where anything over 50 suggests depression. In a pilot study of 36 depressed and 43 non-depressed patients, the average MDDScores were 85.5 for depressed patients and 32.9 for others. A follow-up replication study of 34 depressed patients found an average score of 81. There were a few false negatives and positives, but the sensitivity and specificity were high, at about 91% and 81%, respectively.

Investigators selected the biomarkers from an initial set of 110 candidates because they helped to distinguish depressed people from non-depressed people. Markers included metabolic, inflammatory, and neurotrophic proteins, among others. Interestingly, in the published study, only four markers were consistently (and significantly) different between the two populations. Whether these four were weighted more heavily in the MDDScore calculation is unknown.

While the results are certainly impressive, they should be taken with a grain of salt. For one thing, there’s no known reason why these nine (or in the paper, only four) proteins should be elevated in depression, or whether they normalize with treatment. Also, subjects were all relatively healthy, not taking NSAIDs or antidepressants, and had no other psychiatric complaints or “unstable medical disorders.” The authors also did not control for demographic factors.

Furthermore, the authors point out that the test cannot differentiate bipolar from unipolar depression (although they’re investigating this) or, for that matter, any other psychiatric condition; it cannot be used to predict vulnerability to depression in someone without clinical symptoms; and it does not reflect the severity or prognosis of a patient’s depression. Nevertheless, the article’s sponsor, Ridge Diagnostics, has already begun marketing the test (at $745 a pop) directly to clinicians and patients (Papakostas GI et al, Molecular Psychiatry 2011;online ahead of print).

TCPR's Take:
There may indeed be some biochemical differences between some depressed patients and non-depressed individuals, and this study may give us some early hints. But the question is certainly still in the research stage. Individuals with depressive symptoms but a negative test still deserve treatment, while a positive MDDScore in the absence of subjective complaints presents an entirely different dilemma. Until the science is made a bit more transparent and more data are obtained—preferably with patients that resemble those we see in practice, and with more controls—we recommend that you save yourself the $745 and steer clear of this test.
General Psychiatry
KEYWORDS antidepressants
    Ccpr octnovdec2020 qa1 headshot spielmans 150x150
    Glen Spielmans, PhD

    L-Methylfolate May Offer Modest Boost to Antidepressants

    More from this author
    www.thecarlatreport.com
    Issue Date: May 1, 2012
    SUBSCRIBE NOW
    Table Of Contents
    Predicting Antidepressant Response
    Can a Blood Test Diagnose Depression?
    Is It Possible that Antidepressants Really Don’t Work?
    Future Developments in Antidepressant Therapy
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.